Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Use of Internal Standards in LC-MS/MS – V 2.0

Posted on By

BA-BE Studies: SOP for Use of Internal Standards in LC-MS/MS – V 2.0

Standard Operating Procedure for Use of Internal Standards in LC-MS/MS Analysis for BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/189/2025
Supersedes SOP/BA-BE/189/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To describe the procedure for selection, preparation, and use of internal standards in LC-MS/MS methods used for the quantitative determination of drug concentrations in biological matrices during BA/BE studies.

2. Scope

This SOP applies to all bioanalytical methods utilizing LC-MS/MS instrumentation for BA/BE studies performed in the bioanalytical laboratory. It covers the handling of internal standards

from procurement to application in study sample analysis.

3. Responsibilities

  • Bioanalytical Scientist: Responsible for the selection, justification, and usage of internal standards during method development and sample analysis.
  • QA Officer: Verifies that the internal standard procedures are followed, documented, and traceable.
  • Lab Technician: Prepares internal standard solutions as per protocol and maintains inventory.

4. Accountability

The Bioanalytical Department Head is accountable for ensuring compliance with this SOP and verifying that the internal standard strategy aligns with regulatory expectations.

See also  BA-BE Studies: SOP for Ensuring Adequate Staffing in Clinical Units - V 2.0

5. Procedure

5.1 Selection of Internal Standards

  1. Select an internal standard (IS) that closely resembles the chemical and physical properties of the analyte.
  2. Preferred internal standards include stable isotope-labeled analogs (e.g., deuterated compounds) or structurally similar compounds.
  3. Document justification of IS selection in method development records using Annexure-1: Internal Standard Selection Justification Form.

5.2 Procurement and Storage

  1. Source internal standards from certified suppliers with certificate of analysis (CoA).
  2. Upon receipt, verify the CoA for purity, molecular structure, and batch details.
  3. Store IS stock solution at recommended conditions (typically -20°C, protected from light).
  4. Record storage information in Annexure-2: Internal Standard Inventory Log.

5.3 Preparation of Internal Standard Solution

  1. Weigh required quantity of IS using calibrated analytical balance and dissolve in appropriate solvent (e.g., methanol or acetonitrile).
  2. Prepare intermediate and working solutions as per validated method SOPs.
  3. Label all prepared solutions with:
    • Name of IS
    • Concentration
    • Date of preparation
    • Expiry date
    • Prepared by
  4. Document preparation details in Annexure-3: Internal Standard Solution Preparation Log.

5.4 Use During Sample Preparation

  1. Add a fixed volume of IS working solution to each calibration standard, quality control (QC) sample, and study sample prior to extraction.
  2. Ensure consistent mixing and processing to maintain uniformity.
  3. Record volumes and sample IDs in the extraction worksheet or Annexure-4: Sample Extraction Log.
See also  BA-BE Studies: SOP for Handling Deviations in PK Sampling Time - V 2.0

5.5 Monitoring and Troubleshooting

  1. Review peak shape, retention time, and area response of the IS in each chromatogram.
  2. Investigate deviations such as inconsistent IS response or peak shifts.
  3. Document any issues and corrective actions taken in Annexure-5: Internal Standard Performance Review Log.

5.6 Disposal of Expired Standards

  1. Dispose of expired IS solutions as per hazardous waste SOPs.
  2. Record disposal activity in Annexure-6: Internal Standard Disposal Log.

6. Abbreviations

  • IS: Internal Standard
  • LC-MS/MS: Liquid Chromatography Tandem Mass Spectrometry
  • BA/BE: Bioavailability/Bioequivalence
  • CoA: Certificate of Analysis
  • QC: Quality Control
  • SOP: Standard Operating Procedure

7. Documents

  1. Internal Standard Selection Justification Form – Annexure-1
  2. Internal Standard Inventory Log – Annexure-2
  3. Internal Standard Solution Preparation Log – Annexure-3
  4. Sample Extraction Log – Annexure-4
  5. Internal Standard Performance Review Log – Annexure-5
  6. Internal Standard Disposal Log – Annexure-6

8. References

  • ICH M10: Bioanalytical Method Validation
  • US FDA Guidance on Bioanalytical Method Validation (2022)
  • WHO Guidelines for Bioanalytical Laboratories
See also  BA-BE Studies: SOP for Medical History Documentation in Healthy Volunteers - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Internal Standard Selection Justification Form

Analyte Selected IS Justification Selected By Date
Drug A Drug A-d5 Stable isotope, same retention time Dr. Rajesh Kumar 15/04/2025

Annexure-2: Internal Standard Inventory Log

IS Name Batch No. Received Date Expiry Date Quantity Location
Drug A-d5 DAI-1125 10/04/2025 09/04/2026 25 mg Freezer-1

Annexure-3: Internal Standard Solution Preparation Log

Date IS Name Concentration Solvent Prepared By
12/04/2025 Drug A-d5 1 µg/mL Methanol Sunita Reddy

Annexure-4: Sample Extraction Log

Sample ID IS Volume Added Operator Date
PL-101 50 µL Ajay Verma 14/04/2025

Annexure-5: Internal Standard Performance Review Log

Date Run ID IS Peak Area Observation Action Taken
15/04/2025 BAE-097 325000 Consistent None

Annexure-6: Internal Standard Disposal Log

Date IS Name Quantity Disposed Disposed By Verified By
17/04/2025 Drug A-d5 5 mg Mahesh Patil QA Officer

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial Issue New SOP QA Head
17/04/2025 2.0 Expanded procedure and annexures added ICH M10 Alignment QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Aerosol: SOP for Preventive Maintenance of HVAC Systems in Manufacturing Areas – V 2.0
Next Post: Elixir Department: SOP for Verification of Final Product Volume – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version